Stockscreener 앱 받기
1.32
1.49%
-0.02
전일 마감가:
$1.34
열려 있는:
$1.34
하루 거래량:
34,839
Relative Volume:
0.94
시가총액:
$64.97M
수익:
$409.70K
순이익/손실:
$-12.00M
주가수익비율:
-5.3988
EPS:
-0.2445
순현금흐름:
$-9.81M
1주 성능:
+3.13%
1개월 성능:
-5.04%
6개월 성능:
-8.97%
1년 성능:
+3.94%
1일 변동 폭
$1.315
$1.34
1주일 범위
$1.22
$1.3594
52주 변동 폭
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.32 | 64.97M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | H.C. Wainwright | Buy |
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova Inc (MNOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MediciNova Inc (MNOV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MediciNova: Interview With Founder And CEO Dr. Yuichi Iwaki About The Biotech - Pulse 2.0
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesEBITDA Estimate Trend - newsline.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
MediciNova receives U.S. patent allowance for ibudilast combo By Investing.com - Investing.com South Africa
MediciNova receives U.S. patent allowance for ibudilast combo - Investing.com
MediciNova Receives Notice of Allowance for New Patent - GlobeNewswire
Medicinova Inc (MNOV) Holds Steady, Consolidating Around the $1.31 MarkCovered Call ETF - newsline.com
MediciNova Inc stock (US58468P2038): Nasdaq biotech share edges higher while valuation metrics stay - AD HOC NEWS
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesFinancial Health Score - newsline.com
MediciNova, Inc. Financial Disclosures & SEC Filings - TradingView
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesPreliminary Results - newsline.com
MNOV Q1 2026 Earnings: EPS Surpasses Estimates with Narrower Loss; No Revenue ReportedEarnings Season Preview - The Legal Advocate
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss Reported, Shares DipEarnings Beat Alert - The Legal Advocate
MNOV Q1 2026 Earnings: EPS Beat Against Estimates, Cash Burn Concerns Weigh on SharesAnnual Earnings Summary - The Legal Advocate
MediciNova Inc stock (US58468P2038): valuation snapshot as biotech progresses MN-001 trial milestone - AD HOC NEWS
D Boral Capital maintains MediciNova (MNOV) buy recommendation - MSN
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MNOV Q1 2026 Earnings: Smaller-than-Expected Loss Highlights Clinical-Stage ValueDividend Earnings Report - newsline.com
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24Cup and Handle - The Legal Advocate
Medicinova (MNOV) Holds Steady at $1.37 as Key Levels Come into FocusNHNL Divergence - newsline.com
MediciNova Completes MN-001-NATG-202 Clinical Trial Evaluating Tipelukast - geneonline.com
MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes - Quiver Quantitative
Fatty liver, high triglyceride diabetes trial hits final patient visit - Stock Titan
MediciNova Announces Completion of Last Patient Last Visit - GlobeNewswire
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesEarnings Cycle Outlook - Newser
MNOV Q1 2026 Earnings: Drug Development Progress Drives Narrower-than-Expected LossHigh Attention Stocks - Newser
MediciNova Inc stock (US58468P2038): biotech eyes IPF and neurology pipeline as investors watch next - AD HOC NEWS
MSN Money - MSN
MediciNova, Inc.Common Stock (NQ: MNOV - FinancialContent
MediciNova stock (US58468P2038): Earnings update after April study news - AD HOC NEWS
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo Finance
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
MediciNova Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MediciNova: Q1 Earnings Snapshot - KTVB
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MediciNova (MNOV) Q1 2026 results show lower loss and $27.3M cash - Stock Titan
Medici Nova Biotechnology (MNOV.US) will release its earnings report after the market closes on May 15. - Moomoo
MediciNova Inc stock (US58468P2038): Biopharma innovator targeting unmet needs - AD HOC NEWS
TradingKey - TradingKey
What Medicinova (MNOV) is doing to earn customer loyalty (Tick Down) 2026-05-08Viral Momentum Stocks - newser.com
MediciNova Is Maintained at Buy by D. Boral Capital - Moomoo
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
Why are smart money investors paying attention to Medicinova (MNOV)? (Institutional Demand) 2026-05-03Popular Picks - newser.com
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest - MarketBeat
MediciNova Heads to ROTH, Puts Late-Stage Pipeline in Investor Spotlight - BriefGlance
MediciNova (NASDAQ: MNOV) proxy targets 247M authorized shares, board elections - Stock Titan
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):